InsiderClue
← All stocks

Metagenomi Therapeutics, Inc.

MGX Net selling
CIK 0001785279 #4736 in the set updated 17 Sep 2026
Bought (12 mo)
$23.40K
out of their own pocket, the only kind of buying there is
Sold (12 mo)
$33.07K
$0.00 on a plan · $0.00 straight out of an exercise
Sold at will
$33.07K
13 of 13 sales
Net
−$9.67K
−$9.67K against sales at will

By person

6 insiders · 15 transactions
Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
Reid Laurence
Director
$23.40K (2)
—
+$23.40K
20,000
0.0529%
$23.60K
—
Irish Jian
See Remarks
—
$12.74K (4)
−$12.74K
668,106
1.77%
$788.37K
+12.1%
Wapnick Pamela
Chief Financial Officer
—
$11.28K (4)
−$11.28K
206,580
0.5468%
$243.76K
+227.6%
Thomas Brian C.
Director
—
$6.79K (1)
−$6.79K
2,510,960
6.65%
$2.96M
+0.6%
Wein Matthew
See Remarks
—
$2.26K (4)
−$2.26K
126,133
0.3339%
$148.84K
+762.0%
Noonberg Sarah B.
Chief Medical Officer
—
—
—
109,135
0.2889%
$128.78K
+8.7%

Individual transactions

15
Insider
Date
Role
Action
Shares
Price
Amount
Reid Laurence
9 Sep 2026
Director
Buy
117
$1.18
$138.06
Reid Laurence
9 Sep 2026
Director
Buy
19,883
$1.17
$23.26K
Wapnick Pamela
8 Sep 2026
Chief Financial Officer
Sell
1,911
$1.16
$2.21K
Irish Jian
8 Sep 2026
See Remarks
Sell
2,140
$1.16
$2.48K
Wein Matthew
8 Sep 2026
See Remarks
Sell
358
$1.16
$414.71
Wein Matthew
5 Jun 2026
See Remarks
Sell
558
$1.30
$724.84
Irish Jian
5 Jun 2026
See Remarks
Sell
3,737
$1.30
$4.85K
Wapnick Pamela
5 Jun 2026
Chief Financial Officer
Sell
2,884
$1.30
$3.75K
Irish Jian
5 Mar 2026
Chief Executive Officer
Sell
1,607
$1.60
$2.57K
Wein Matthew
5 Mar 2026
See Remarks
Sell
482
$1.60
$771.20
Wapnick Pamela
5 Mar 2026
Chief Financial Officer
Sell
1,581
$1.60
$2.53K
Irish Jian
5 Dec 2025
Chief Executive Officer
Sell
1,602
$1.77
$2.84K
Wapnick Pamela
5 Dec 2025
Chief Financial Officer
Sell
1,576
$1.77
$2.79K
Wein Matthew
5 Dec 2025
See Remarks
Sell
199
$1.77
$352.61
Thomas Brian C.
5 Dec 2025
Director
Sell
3,830
$1.77
$6.79K

What was left out

Form 4 filings counted 25
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 0
Sales straight out of an exercise 0
Sales at will 13
Transactions with no price 0
Shares from compensation/vesting 773,962
History held since 14 Feb 2024